Back to Hematology
Hematologyv2005, Age-adjusted 2014Evidence-Based

Hematopoietic Cell Transplantation-specific Comorbidity Index (HCT-CI)

Predicts survival after HCT in patients with hematologic malignancies, including optional age adjustment. The HCT-CI comprises 17 different categories of organ dysfunction and has been validated as more sensitive than the Charlson Comorbidity Index for HCT patients.

Clinical Input Parameters

years
Range: 0 — 100 years
Clinical Assessment
Awaiting Parameters
hct ci score
—points
Ready to Calculate

Awaiting Clinical Input

Enter the clinical input parameters on the left and click Run Clinical Assessment to evaluate this medical calculator with deterministic clinical scoring.

Open in Web App
Clinical decision support tool for licensed medical practitioners. Confirm independently before prescribing or clinical action.

When & Why to Use

The Hematopoietic Cell Transplantation-specific Comorbidity Index (HCT-CI) is utilized in clinical practice for risk stratification, diagnostic probability estimation, and treatment decision-making within hematology.

Use this tool during initial patient intake, emergency department workup, or bedside assessment when objective clinical scoring is required to guide management or admission decisions.

Clinical Formula & Scoring Logic

Sum of points assigned to each comorbidity: Arrhythmia (1), Cardiac CAD/CHF/MI/EF≤50% (1), Cardiac valve disease (3), IBD (1), Diabetes treated (1), Cerebrovascular (1), Psychiatric (1), Mild hepatic (1), Moderate/severe hepatic (3), Obesity BMI>35 (1), Infection (1), Rheumatologic (2), Peptic ulcer (2), Moderate/severe renal (2), Moderate pulmonary (2), Severe pulmonary (3), Prior solid tumor (3). Age adjustment adds 1 point if age ≥40 years.

Clinical Pearls & Practice Notes

  • Pulmonary dysfunction definitions: Mild = DLco and/or FEV1 81-90% or dyspnea on moderate exertion; Moderate = DLco and/or FEV1 66-80% or dyspnea on slight activity; Severe = DLco and/or FEV1 ≤65% or dyspnea at rest or requiring oxygen
  • Hepatic dysfunction definitions: Mild = chronic hepatitis, bilirubin > ULN to 1.5x ULN, or AST/ALT > ULN to 2.5x ULN; Moderate/severe = liver cirrhosis, bilirubin >1.5x ULN, or AST/ALT >2.5x ULN
  • Renal dysfunction: Moderate/severe = serum creatinine >2 mg/dL, on dialysis, or prior renal transplant
  • Rheumatologic diseases include: SLE, RA, polymyositis, mixed CTD, polymyalgia rheumatica
  • Consider other factors including disease stage and donor characteristics in transplant decision-making

Evidence & Literature Citations

  1. Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005 Oct 15;106(8):2912-9.
  2. Sorror ML, Sandmaier BM, Storer BE, Franke GN, Laport GG, Chauncey TR, et al. Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation. J Clin Oncol. 2014 Oct 10;32(29):3249-56.
  3. Sorror ML, Martin PJ, Storb RF, Bhatia S, Maziarz RT, Pulsipher MA, et al. Pretransplant comorbidities predict severity of acute graft-versus-host disease and subsequent mortality. Blood. 2014 Jul 10;124(2):287-95.

Score Interpretation Ranges

Low Risk0 – 0 pts

Score 0

Intermediate Risk1 – 2 pts

Score 1-2

High Risk3 – 27 pts

Score ≥3

Need Clinical Suite Access?

Run this calculator with patient history, laboratory integration, and drug interaction safety checks on the DexaMed clinician app.

Open in Web App

Clinical Decision Support (CDS) Notice & Legal Disclaimer

This medical calculator and its scoring interpretation are provided strictly for licensed healthcare professionals and medical trainees as an educational and clinical decision support instrument. It does not replace independent clinical judgment, comprehensive patient history, physical examination, or attending physician oversight. Not FDA-cleared as an autonomous diagnostic medical device. Read the full DexaMed Medical Disclaimer.